This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
JACC Specialty Journals
JACC: CardioOncology – Cardiac Side-Effects of Alectinib in Patients with ALK-Positive Lung Cancer: Outcomes of Dedicated Cardio-Oncology Follow-Up
Released: Feb 21, 2023
Commentary by Dr. Lavanya Kondapalli
JACC: CardioOncology – Cardiac Side-Effects of Alectinib in Patients with ALK-Positive Lung Cancer: Outcomes of Dedicated Cardio-Oncology Follow-Up
00:00:00
